In this study, C150 treatment resulted in increased expression of the epithelial markers ZO-1 and claudin-1 in pancreatic cancer cells, both of which are integral components of tight junctions in cells with an epithelial phenotype. Here, CLDN1 is linked to pancreatic neoplasm.